Social network
Investors - Ensuring sustainable growth
Investors - Ensuring sustainable growth

Investors

Ensuring sustainable growth

IR Thematic Call on sarilumab

November 09, 2015

Sanofi and Regeneron hosted a conference call for the financial community on sarilumab during the upcoming American College of Rheumatology Annual (ACR) Meeting in San Francisco. The conference call included a presentation followed by a Q&A session.

Sarilumab is a fully-human monoclonal antibody directed against the IL-6 receptor (IL-6R). This investigational compound is currently in clinical development for Rheumatoid Arthritis. Sarilumab achieved primary efficacy endpoints across all completed pivotal Phase 3 studies, including for TARGET and ASCERTAIN. Data from these two studies were presented as oral presentations at ACR on November 8th.

 

Related Press releases

 

Right area:

Stock Market

IR mobile application

SANOFI IR - The Investor Relations Mobile Application

Download SANOFI IR on smartphone and tablet!

 

Your services